U.S. Markets open in 3 hrs 32 mins

Santarus (SNTS) in Focus: Stock Advances 6.2%

Zacks Equity Research

Santarus, Inc. (SNTS) was a big mover last session, as the company saw its shares rise by over 6% on the day. The move came on the back of solid volume too, as far more shares changed hands than in a normal session. This price movement is a reversal for this biotechnology company, as the stock moved down more than 5% over the past one-month time period.

The company has seen 3 positive revisions in the past few weeks and its earnings consensus has moved up over the past two months, suggesting there could be more solid trading down the road for SNTS. So make sure to keep an eye on this stock going forward to see if this recent jump can turn into more strength down the road.

Santarus currently has a Zacks Rank #3 (Hold) and its Earnings ESP is 0.00%.

Some better performing biotechnology stocks include Elan Corporation, plc (ELN), Jazz Pharmaceuticals Public Limited Company (JAZZ) and Lannett Company, Inc. (LCI). All these carry a Zacks Rank #2 (Buy).

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report >>

Read the Full Research Report on SNTSRead the Full Research Report on ELNRead the Full Research Report on JAZZRead the Full Research Report on LCIZacks Investment Research